FLUBLOK TRIVALENT NORTHERN HEMISPHERE
INFLUENZA A VIRUS A/Missouri/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/Darwin/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/Pennsylvania/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN
Listed by Sanofi Vaccines US Inc.
- Strength
- 45 ug/.5mL, 45 ug/.5mL, 45 ug/.5mL
- Form
- Injection
- Route
- Intramuscular
What it contains
- Influenza A Virus A/missouri/11/2025 (h1n1) Recombinant Hemagglutinin Antigen 45 ug/.5mL
- Influenza A Virus A/darwin/1415/2025 (h3n2) Recombinant Hemagglutinin Antigen 45 ug/.5mL
- Influenza B Virus B/pennsylvania/14/2025 Recombinant Hemagglutinin Antigen 45 ug/.5mL
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
FDA record
| Dosage form | Injection |
|---|---|
| Route | Intramuscular |
| Approval route | BLA — biologic licence |
| NDC code | 49281-726 |
| FDA application | BLA125285 |
| Package sizes listed | 1 |
| Marketed since | July 2026 |
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.